The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial
In this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.
Authors
- Shawn E. Young
- Timothy L. Beard
- Maki Yamamoto (ORCID: https://orcid.org/0000-0003-0613-1354)
- Mark Cripe
- A. Milford Ward (ORCID: https://orcid.org/0009-0003-2201-8850)
- Parth Shah
- J. Michael Guenther
- Brenda Sickle-Santanello
- Stanley P. Leong
- Samuel Dierks
Institutions
- OhioHealth (US)
- University of California, Irvine (US)
- California Pacific Medical Center (US)
- University of Tennessee Medical Center (US)
- St. Elizabeth Healthcare (US)
- Columbus Oncology and Hematology Associates (US)
- Summit Medical Group (United States) (US)
- Pacific Medical (China) (CN)
- University of Tennessee at Knoxville (US)
- Ergon Energy (Australia) (AU)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1080/14796694.2026.2640227
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00